source
- RevMed's Rasonque shows weaker response in common KRAS pancreatic cancer mutation, shares fall over 6%New data from Revolution Medicines indicates that its KRAS inhibitor Rasonque had a reduced response rate in patients whose pancreatic tumors carry the most common KRAS mutation. The subgroup resp…
- Biotech Index Retraces Gains as Weak Trial Data and Market Fears WeighBioPharma Dive’s latest data‑visualization piece examines why biotech stocks have slipped recently and highlights the rapid pace of startup acquisitions this year. The XBI index, a barometer for b…